January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Two Icon Pipeline Two Header 

Cambridge Healthtech Institute’s 3rd Annual
Antibody-Drug Conjugates
Engineering for Clinical Success
January 19-20, 2016

ADCs have reached an exciting point in development where engineering success has led to more than 30 ADCs in clinical trials, with more on the way. Cambridge Healthtech Institute’s Antibody-Drug Conjugates conference reveals the engineering that has brought about today’s revolution, and examines how to design safe and effective ADCs. In addition, strategies for advancing ADCs to the clinic will be discussed along with considerations for clinical trial design. Analyzing ADCs to explore conjugation, stability, payloads and tumor penetration will also e addressed in this leading ADC event.

Preliminary Agenda 


Antibody Drug Conjugates – Past, Present and Future

Nancy Whiting, Pharm.D., BCOP, Executive Director & Head, Medical Affairs, Seattle Genetics

Translatability of Nonclinical Safety Findings of ADCs 

Mary J. Hinrichs, Ph.D., Principal Toxicologist, Biologics Safety Assessment, MedImmune


Molecular Integrity of Antibody-Drug Conjugates: Applying Preclinical Learnings to the Clinic

Brooke Rock, Ph.D., Senior Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

Brentuximab Vedotin as Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with Hodgkin’s Lymphoma at Risk of Relapse or Progression (AETHERA)

Auayporn P. Nademanee, M.D., Jan & Mace Siegel Professor, Hematology & Hematopoietic Cell Transplantation, Associate Clinical Director, Hematology & Hematopoietic Cell Transplantation, and Director, Matched Unrelated Donor (MUD) Program, City of Hope


Therapy of Advanced Solid Cancers with Sacitumab Govitecan (IMMU-132), a Novel ADC Targeting SN-38

David M. Goldenberg, M.D., Professor and President, Garden State Cancer Center and Chairman, Chief Scientific & Chief Medical Officer, Immunomedics, Inc.

XMT-1522: A Novel Anti-HER2 ADC for the Treatment of Low HER2-Expressing Tumors and Combination with Trastuzumab-Based Regimens in HER2-Driven Tumors

Peter U. Park, Ph.D., Vice President, Biology, Mersana Therapeutics, Inc.


Impact of Disulfide Linker Variation on Antibody-Drug Conjugate in vitro and in vivo Properties

Peter Dragovich, Ph.D., Principal Scientist, Medicinal Chemistry, Genentech, Inc.

Methods to Make Homogenous Antibody Drug Conjugates

Aaron K. Sato, Ph.D., Vice President, Research, Sutro Biopharma, Inc.


Probody Therapeutics and the Target Landscape for Drug Conjugates

Jonathan Terrett, Ph.D., Senior Director Oncology, CytomX Therapeutics, Inc.

Stable and Efficacious Site-Specific ADCs of Unmodified Antibodies

Sean Hu, Ph.D., Senior Vice President, R&D, Dophen Biomed

For questions about the meeting, please contact: 

For partnering & sponsorship information, please contact: 

Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
Phone: 781-972-5421
Email: mruberry@healthtech.com 

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com 

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com